



Cytokine response during non-cerebral and cerebral malaria: evidence of a failure to control inflammation as a cause of death in African adults

Yakhya Dieye¹, Babacar Mbengue^{2,3}, Shobha Dagamajalu⁴,
Mouhamadou Mansour Fall⁵, Mun Fai Loke⁴, Cheikh Momar Nguer⁶,
Alassane Thiam³, Jamuna Vadivelu⁴ and Alioune Dieye^{2,3}

¹ Vice-Chancellor's Office, University of Malaya, Kuala Lumpur, Malaysia

² Département d'Immunologie, Faculté de Médecine, de Pharmacie et d'Odontostomatologie, Université Cheikh Anta Diop de Dakar, Dakar, Sénégal

³ Unité d'Immunogénétique, Institut Pasteur de Dakar, Dakar, Sénégal

⁴ Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

⁵ Service de Réanimation, Hôpital Principal de Dakar, Dakar, Sénégal

⁶ Département Génie Chimique et Biologie Appliquée, École Supérieure Polytechnique, Université Cheikh Anta Diop de Dakar, Dakar, Sénégal

ABSTRACT

Background. With 214 million cases and 438,000 deaths in 2015, malaria remains one of the deadliest infectious diseases in tropical countries. Several species of the protozoan *Plasmodium* cause malaria. However, almost all the fatalities are due to *Plasmodium falciparum*, a species responsible for the severest cases including cerebral malaria. Immune response to *Plasmodium falciparum* infection is mediated by the production of pro-inflammatory cytokines, chemokines and growth factors whose actions are crucial for the control of the parasites. Following this response, the induction of anti-inflammatory immune mediators downregulates the inflammation thus preventing its adverse effects such as damages to various organs and death.

Methods. We performed a retrospective, nonprobability sampling study using clinical data and sera samples from patients, mainly adults, suffering of non-cerebral or cerebral malaria in Dakar, Sénégal. Healthy individuals residing in the same area were included as controls. We measured the serum levels of 29 biomarkers including growth factors, chemokines, inflammatory and anti-inflammatory cytokines.

Results. We found an induction of both pro- and anti-inflammatory immune mediators during malaria. The levels of pro-inflammatory biomarkers were higher in the cerebral malaria than in the non-cerebral malaria patients. In contrast, the concentrations of anti-inflammatory cytokines were comparable in these two groups or lower in CM patients. Additionally, four pro-inflammatory biomarkers were significantly increased in the deceased of cerebral malaria compared to the survivors. Regarding organ damage, kidney failure was significantly associated with death in adults suffering of cerebral malaria.

Conclusions. Our results suggest that a poorly controlled inflammatory response determines a bad outcome in African adults suffering of cerebral malaria.

Submitted 7 December 2015

Accepted 2 April 2016

Published 2 May 2016

Corresponding author

Yakhya Dieye, y.dieye@laposte.net

Academic editor

Erika Braga

Additional Information and
Declarations can be found on
page 15

DOI 10.7717/peerj.1965

© Copyright
2016 Dieye et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Parasitology, Global Health, Immunology, Infectious Diseases

Keywords Malaria, Cerebral, *Plasmodium falciparum*, Cytokine, Inflammation

INTRODUCTION

Despite a decade of sustained efforts that have substantially reduced mortality and morbidity due to malaria, this disease continues to represent an important health concern in tropical countries (White et al., 2014). According to the World Health Organization (WHO), there were 214 million cases of malaria worldwide in 2015, which resulted in 438,000 deaths (WHO, 2015). Ninety percent of the victims were from Africa, 74% being children under five years of age. Malaria is endemic in many sub-Saharan African countries. However, there are disparities between (WHO, 2015) and even within countries (Espie et al., 2015) regarding the transmission of the disease. In many rural areas where the local environment favors the development of the mosquito vector and its interactions with humans, transmission of malaria is high and perennial (Trape et al., 2014). In contrast, in other areas including urban zones, the transmission of malaria is low to moderate and seasonal (White et al., 2014). Individuals living in regions of high and stable transmission progressively acquire immunity after experiencing and surviving to several infections (Olliaro, 2008). This immunity protects against severe, life-threatening cases of malaria but does not confer a sterile protection (Doolan, Dobano & Baird, 2009). In these areas, clinical malaria occurs in young children while healthy carriage of the parasite is common in adults. Adults who die of malaria typically are pregnant women or non-immune individuals from low transmission zones.

There was a decline of 18% and 48% of global malaria cases and deaths respectively between 2000 and 2015. This success was primarily due to a drastic reduction of malaria transmission by widespread use of insecticide-treated bednets and the availability of artemisinin-based treatments (Bhatt et al., 2015; White et al., 2014). The decline of malaria is expected to continue with the support of the WHO Global Technical Strategy for malaria 2016–2030 that aims to reduce its global incidence and mortality by at least 90% by 2030 (WHO, 2015). However, a continuous decrease of malaria prevalence and especially a sustained reduction of transmission in currently holoendemic zones may result, in the future, in an increase of the number of adults susceptible to severe cases. Such an unwanted but possible scenario potentially represents a future public health concern in sub-Saharan African countries. Several species of the protozoan *Plasmodium* cause malaria. However, almost all the deaths are due to *P. falciparum*, a species that causes the severest cases including cerebral malaria (Storm & Craig, 2014). In response to *P. falciparum* infection, a robust immune inflammatory response takes place. An important component of this response is the production of inflammatory immune mediators whose actions are crucial for the control of the parasites (Deloron et al., 1994; Lyke et al., 2004; Sarthou et al., 1997). This inflammatory response is rapidly followed by the production of anti-inflammatory cytokines that downregulate the inflammation preventing detrimental immune reactions (Kurtzhals et al., 1998; Peyron et al., 1994; Walther et al., 2005). Therefore, the immune response to *P. falciparum* infection includes a subtle balance of pro- and anti-inflammatory immune mediators (Crompton et al., 2014; Frosch & John, 2012). A rupture of this balance is at the basis of the events that lead to organ damage and death (Crompton et al., 2014). The pathogenesis of severe malaria and its associated mortality have been widely studied

in children. In contrast, there are less investigations that addressed these aspects of the disease in adults, in particular from Africa (*Olliaro, 2008*). In this study, we performed a retrospective analysis of the available clinical data and of the immune response of malaria patients, mainly adults, admitted at the Hôpital Principal de Dakar, Sénégal. Malaria is endemic in several areas in Sénégal. However, the capital city Dakar and its surroundings constitute a zone of low prevalence of malaria with a seasonal transmission. We report the analysis of the serum levels of cytokines, chemokines and growth factors in control individuals and in patients suffering of non-cerebral (NCM) or cerebral malaria (CM). All the CM patients were adults and included deceased and survivors enabling to gain insights into the effect of the analysed biomarkers in the outcome of the disease.

MATERIALS AND METHODS

Study population, ethics, consent and permissions

This study was performed on serum samples from patients diagnosed with malaria at the Hôpital Principal de Dakar, Sénégal between October 2012 and December 2014 (*Torrentino-Madamet et al., 2014*). The samples were taken after written consents from the patients or their accompanying family members. The controls corresponded to samples obtained from healthy volunteers residing in Dakar. This study was approved by the Université Cheikh Anta Diop de Dakar's institutional research ethics committee (Protocol No 001/2015/CER/UCAD). Venous blood samples were collected in Vacutainer[®] ACD tubes (Becton Dickinson, Rutherford, NJ, USA) prior to patient treatment. *Plasmodium* presence and density in blood samples were determined by microscopic examination of thin blood smears stained with a 10% May-Grünwald Giemsa solution (SigmaR, St-Louis, MO, USA). *P. falciparum* was the only species found. Blood parameters were determined at the hospital's clinical laboratory. The following criteria were used for enrollment into the two groups of malaria patients. Life-threatening CM was defined following the WHO criteria as the presence of *P. falciparum* in blood smears accompanied by a coma with no other cause of cerebral symptoms. NCM cases were defined by fever and presence of *P. falciparum* in blood smear, without other infections or symptoms of severe malaria as defined by the WHO (*WHO, 2000*). CM patients were treated according to a protocol based on the Senegalese national recommendations that consisted of intramuscular administrations of 20 mg/kg quinine every eight hours. NCM patients were treated with oral administration of 20 mg/kg of artesunate derivatives or quinine. Secondary samples analyzed in this study corresponded to blood taken from survivors of CM (14 individuals) before patient release from the hospital (1–15 days after admission).

Biomarker measurement

Serum biomarkers were measured using a Milliplex MAP kit for human cytokine/chemokine magnetic bead panel (catalogue # HCYTMAG-60K-PX29; EMD Millipore Corporation, Billerica, MA, USA) according to the recommendations of the manufacturer. The levels of 29 biomarkers were measured in each sample including interleukin (IL)-1 α , IL-1 β , IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, interferon (IFN) α 2, IFN γ , IFN-inducible protein 10 (IP-10,

CXCL-10), epidermal growth factor (EGF), eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF) α , TNF β , monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1 α , MIP-1 β , and vascular endothelial growth factor (VEGF). The measurements were performed in 25 μ l of undiluted serum samples on one 96 well plate. Each well contained fluorescent-coded magnetic microbeads coated with analyte-specific capture antibodies to simultaneously measure the biomarkers in a specimen. Seven standards and two quality-control (QC) samples were included and measured in duplicate. The QC samples corresponded to mixtures with two values (high and low) for each biomarker. After the capture of the biomarkers, the beads were washed, incubated with biotinylated antibodies and then with streptavidin-PE. Excitation and fluorescence acquisition from the beads were performed using a Luminex 200TM equipped with an xPONENTTM software version 3.1 (Luminex, Austin, TX, USA) that calculated the concentrations of the biomarkers by extrapolating the mean fluorescence intensity (MFI) to a 5-parameter weighted logistic regression curve from the standards. Any measurement below the detection limit was given a value of 0 for the corresponding analyte. For most of the biomarkers, the majority of the samples had detectable values. For IL-2, IL-3, IL-4, IL12p40, IL-13 and TNF β , the small number of samples with detectable MFI did not permit meaningful statistical analyses. These biomarkers were excluded from the statistical analyses. The MFI for one G-CSF and two IL-1RA samples were above the value of the highest standard whose concentration was 10,000 pg/ml. These samples were arbitrarily assigned concentrations above the highest standard. The G-CSF sample was assigned a concentration of 11,000 pg/ml. The two IL-1RA samples were attributed concentrations of 11,000 pg/ml and 12,000 pg/ml respectively according to the values of their MFI. Treating the samples above the highest standard in this way, rather than excluding them, allowed to take them into account when determining the median values for G-CSF and IL-1RA.

Statistical analyses

The statistical analyses were carried out using the IBM SPSS 22.0 software. Non-parametric tests were used to compare the levels of biomarker and their correlation with other variables across different groups. Mann–Whitney U test and Kruskal–Wallis one-way ANOVA were used to compare data across two and three groups respectively. Wilcoxon matched pairs signed rank test was used to compare biomarker levels in sera from CM patients at admission and at their release from the hospital. Correlation tests were performed using Spearman’s Rho rank test. Pearson Chi-Square was used to test association of organ failure with outcome in CM patients. Benjamini–Hochberg correction was used for multiple testing adjustment. For all the statistical analyses, a p value < 0.05 was considered as significant except when multiple testing adjustment was used, in which cases significant p values depended on the critical values from the Benjamini–Hochberg correction. The biomarker profiles were determined as previously described (*Da Costa et al., 2014*). In brief, the median value in the global population (CT + NCM + CM) was calculated for each biomarker and used as a cut-off to determine the percentage of individuals that had “high” (above the median value) and “low” (below the median value) levels of biomarker

in the CT, NCM and CM groups. An ascendant biomarker profile was then constructed in the CT group by assembling the biomarkers from the one having the smallest percentage of high producers to the one having the largest. The resulting ascendant curve was used as a reference to visualize the variation of the percentage of high producers of biomarkers in the other groups (Fig. 1). In addition to showing the differences in the percentage of high producers (descriptive statistics), the biomarker profiles also indicate the analytes (hatched bars) for which there was a significant difference in adjusted Mann–Whitney U pairwise comparison (inferential statistics).

RESULTS

Study population and clinical data

We performed a retrospective, nonprobability sampling study using sera samples from healthy individuals and from patients admitted at the Hôpital Principal de Dakar, Sénégal. The cohort included 17 and 27 subjects diagnosed with NCM and CM respectively, and 18 healthy controls (CT) (Table 1). The three groups of individuals were comparable in age and gender, and were mainly composed of adults (Table 1). Subjects below 15 years of age included six children aged 5–13 diagnosed with NCM. Several clinical and blood parameters existed but were not recorded for all the individuals preventing reliable statistical analyses. Available data showed, as expected, hemoglobin levels comparable in the CT and NCM individuals while significantly lower in the CM patients (Table 1). Additionally, parasitemia was comparable between the NCM and CM groups (Table 1). Regarding organ defect in the CM group, kidney failure was the most frequent (13/27) followed by liver, hematologic and respiratory malfunction, while hemodynamic failure was rare (Table 1). All the NCM patients were successfully treated, while 9/27 CM subjects died.

Levels of inflammatory but not of anti-inflammatory biomarkers were higher in CM than in NCM patients

To analyze the production of immune mediators during malaria, we measured the serum levels of 29 biomarkers including growth factors, chemokines, inflammatory and anti-inflammatory cytokines. We determined the ascendant biomarker profile of the CT group as previously described (Da Costa *et al.*, 2014) and plotted the resulting curve on the profiles of the NCM and CM patients (Fig. 1). The biomarker profiles display comparison of the proportion of individuals with levels of analytes above the global median between the controls and the malaria patients (Figs. 1B and 1C). Additionally, analytes that significantly differ in Mann–Whitney U pairwise comparison after Benjamini–Hochberg multiple testing adjustment are shown in the biomarker profiles (Figs. 1B and 1C, hatched bars). Several analytes were significantly higher in malaria patients (NCM and/or CM) than in CT individuals (Figs. 1 and 2). These biomarkers included most of the pro-inflammatory cytokines and chemokines tested (IL-1 α , IL-6, IL-8, IL-12p70, IL-15, IL-17A, IP-10, TNF α , IFN α 2, IFN γ , MIP-1 α , MIP-1 β and MCP-1) and the anti-inflammatory cytokines IL-10 and IL-1RA. The induction of both inflammatory and anti-inflammatory immune mediators that aims to respond to the infection while controlling the level of inflammation in order to prevent damages to host organs has been well documented in malaria patients




Figure 1 Serum levels of immune mediators during malaria. The levels of 29 biomarkers were measured in control subjects (CT) and in non-cerebral (NCM) and cerebral (CM) malaria patients. The median value of each cytokine in the global population (CT + NCM + CM) was used as a cut-off value to determine the percentage of “high” (above median) biomarker producer individuals in each group. The ascendant biomarker profile of the CT (A) was determined and the resulting curve used as a reference to visualize the difference in the proportion of high biomarker producers with the NCM (B) and CM (C) groups. Hatched bars represent biomarkers for which there is a significant difference in Mann–Whitney U pairwise comparison with the CT reference group after Benjamini–Hochberg multiple test adjustment.

Table 1 Demographic, clinical, and disease outcome data.

		CT	NCM	CM	Total
Gender	Male	11	11	22	44
	Female	7	6	5	17
Age	Range	23–57	5–74	15–80	5–80
	Median	28.5	18	26	26
HB	Normal	18	17	11	46
	Low	0	0	16	16
Parasitemia	Median	0	520	1,452	1,022 ³
	IQR	0	2,552	9,981	7,654 ⁴
Outcome	Survived	18	17	18	53
	Deceased	0	0	9	9
Organ failure	Neurological	0	0	27	27
	Respiratory	0	0	6	6
	Kidney	0	0	13	13
	Liver	0	0	8	8
	Hematologic	0	0	7	7
	Hemodynamic	0	0	2	2

Notes.

CT, Control Individuals; NCM, Non-cerebral Malaria Patients; CM, Cerebral Malaria Patients; HB, Hemoglobin (Low, <100 g/L; Normal, >100 g/L); IQR, Inter Quartile Range.

³Value for NCM + CM.

(Frosch & John, 2012). Also, we observed an induction of Th1 (IL-12, IFN γ and TNF α) and Th2 (IL-10) biomarkers in both NCM and CM patients. Since only the control group included children, we performed pairwise comparisons after removing subjects below 15 years of age. We did not find differences in the analytes that significantly differed whether children were included or not except for IFN α 2 that lost significance in the CT/NCM comparison (not shown). Besides individual biomarkers, several analytes were significantly positively correlated consistent with the immune response during malaria that mobilizes several cytokines, chemokines and growth factors (File S1). Next, we analyzed the difference of cytokine levels between the NCM and CM patients. Most of the biomarkers induced during malaria were higher in CM than in the NCM individuals (Fig. 3). However, after Benjamini–Hochberg adjustment for multiple tests (Table 2), only the levels of the pro-inflammatory IL-6 and IL-8, and of IL-1RA, an antagonist of IL-1 reached statistical significance (Fig. 3 and Table 2). These results indicate an inflammatory response of higher magnitude in CM compared to NCM patients as previously mentioned in several reports (Crompton et al., 2014). In contrast, the level of IL-10 was not significantly different between NCM and CM patients (Fig. 3). Additionally, the level of IL-5, a Th2 anti-inflammatory cytokine, was significantly lower in CM than in NCM patients (Fig. 3 and Table 2) as was the ratios of IL-5 to the pro-inflammatory biomarkers TNF α , IP-10 and IL-8 (not shown). These results suggest that the level of anti-inflammatory response did not match the strength of the inflammatory cytokine response in the CM patients.




Figure 2 Serum biomarker levels in control individuals and in non-cerebral and cerebral malaria patients. Biomarkers that significantly differed across the three groups in Kruskal–Wallis test after Benjamini–Hochberg adjustment are shown. Box plots represent medians with 25th and 75th percentiles, bars 10th and 90th percentiles, and dots outliers for biomarker concentrations. P, p[i] values in Kruskal–Wallis tests. C, critical values in Benjamini–Hochberg correction. (continued on next page...)

Levels of inflammatory biomarkers were lower in survivors than in deceased of CM

Failure to control inflammation is proposed as one of the mechanisms leading to CM, which is consistent with the difference we observed between NCM and CM patients. To




Figure 2 (...continued)

further analyze the effect of the inflammatory biomarkers, we compared the levels of analyte between the survivors ($n = 18$) and the deceased ($n = 9$) of CM. Interestingly, after multiple testing adjustment (Table 3), there were four biomarkers whose levels significantly differed between the two groups. All were pro-inflammatory analytes (Eotaxin, IL-15, MCP-1 and $\text{TNF}\alpha$) that were significantly lower in the survivors than in the deceased of CM (Fig. 4). These results suggest that the cause of death involved an inflammatory response of high




Figure 2 (...continued)

magnitude that was not properly controlled. To analyze possible effects of the inflammatory response in tissue damage, we compared the failure of different organs between survivors and deceased CM patients. Kidney failure was significantly associated with patient's death ($\chi^2(1, N = 27) = 8.98, p = 0.003$; Effect Size = 0.58) while the occurrence of neurological, respiratory, liver, hematologic and hemodynamic failures were comparable between the two groups. We further attempted to correlate the biomarker levels with organ failure.




Figure 3 Levels of inflammatory immune mediators are higher in cerebral than in non-cerebral malaria patients. The ascendant biomarker profile curve of the NCM (line) was plotted on the CM graph (bars) to visualize the difference in the proportion of high biomarker producers. Hatched bars represent biomarkers for which there is a significant difference in Mann–Whitney U pairwise comparison between the two groups after Benjamini–Hochberg multiple test adjustment.

Table 2 Biomarkers significantly differing between non-cerebral and cerebral malaria patients after multiple testing adjustment.

Biomarkers	MW <i>P</i> values	BH critical values	Significance
TNFα ^a	0.049	0.017	No
IL-15 ^a	0.042	0.013	No
MCP-1 ^a	0.013	0.010	No
IL-6 ^a	0.008	0.008	Yes
IL-1RA	0.007	0.006	Yes
IL-5 ^b	0.002	0.004	Yes
IL-8 ^a	0	0.002	Yes

Notes.

MW, Mann–Whitney U comparison; BH, Benjamini–Hochberg correction.

^aIncreased in CM.

^bDecreased in CM.

Kidney failure showed significant moderate to strong positive correlations with several chemokines and pro-inflammatory cytokines (Table 4), while respiratory, hematological and liver failure displayed weak positive correlations with 5, 5 and 1 biomarkers respectively (not shown).

Variation of biomarker levels before and after cerebral malaria treatment

Analysis of biomarker profiles in malaria patients before and after treatment provides valuable information on immune mediators that are induced during malaria. We compared the levels of biomarker between the time of emergency admission and of hospital release in




Figure 4 Levels of inflammatory immune mediators are higher in deceased than in survivors of cerebral malaria. The ascendant biomarker profile curve of the survivors (line) was plotted on the deceased graph (bars) to visualize the difference in the proportion of high biomarker producers. Hatched bars represent biomarkers for which there is a significant difference in Mann–Whitney U pairwise comparison between the two groups after Benjamini–Hochberg multiple test adjustment.

Table 3 Biomarkers significantly increased in deceased of cerebral malaria compared to survivors.

Biomarkers	MW <i>P</i> alues	BH critical values	Significance
IL-6	0.027	0.015	No
IL-8	0.017	0.010	No
Eotaxin	0.007	0.008	Yes
TNF α	0.003	0.006	Yes
IL-15	0.002	0.004	Yes
MCP-1	0.001	0.002	Yes

Notes.

MW, Mann–Whitney U comparison; BH, Benjamini–Hochberg correction.

Table 4 Biomarkers correlated with kidney failure in cerebral malaria patients.

	ρ (<i>p</i> value)		ρ (<i>p</i> value)		ρ (<i>p</i> value)
Eotaxin	0.514 (0.006)	IL-10	0.457 (0.017)	IL-1 α	0.593 (0.001)
G-CSF	0.500 (0.008)	IL-12p70	0.445 (0.020)	IP-10	0.533 (0.004)
GM-CSF	0.714 (<0.001)	IL-15	0.621 (0.001)	MCP-1	0.581 (0.002)
IFN α 2	0.525 (0.005)	IL-17A	0.401 (0.038)	TNF α	0.542 (0.003)
IFN γ	0.529 (0.005)	IL-1RA	0.390 (0.044)		

Notes.

ρ , Spearman's Rho coefficient.

Table 5 Variation of biomarker levels between admission and release from hospital in cerebral malaria patients.

	Admission (pg/ml) MN \pm SD/MD	Release (pg/ml) MN \pm SD/MD	P value
G-CSF	651 \pm 1,869/163	116 \pm 111/99	0.007
IL-10	1,848 \pm 1,749/464	99 \pm 165/40	0.002
TNF α	90 \pm 101/60	24 \pm 14/20	0.002
IL-1 α	121 \pm 165/76	57 \pm 80/28	0.013
IL-8	213 \pm 417/66	58 \pm 152/14	0.001
IP-10	5,668 \pm 6,297/2,496	1,757 \pm 2,191/892	0.002
MCP-1	1,303 \pm 1,754/508	409 \pm 678/242	0.005

Notes.

Admission, biomarker levels at the time of hospital admission of CM patients; Release, biomarker levels at the time of release of CM patients from hospital; P value, two-tailed p value of a Wilcoxon Rank test; MN, mean; SD, standard deviation; MD, median.

14 CM patients (Table 5). Wilcoxon rank test showed 7 biomarkers (G-CSF, IL-10, IL-1 α , IL-8, IP-10, MCP-1, TNF α) that were significantly different between the two time points after Benjamini–Hochberg adjustment. All these biomarkers were lower in the second samples confirming the induction of different types of immune mediators including growth factor (G-CSF), inflammatory (TNF α , IL-1 α , IP-10), anti-inflammatory (IL-10) and chemokines (IL-8, MCP-1) during immune response to malaria (Table 5).

DISCUSSION

Inflammation and outcome of cerebral malaria

In this study, we performed a retrospective analysis of 18 controls, and of 17 and 27 NCM and CM patients respectively. The CM patients included 18 survivors and nine (30%) deceased subjects, a proportion similar to the highest mortality rates reported for CM. Beside neurological defect, kidney failure was the most frequent organ malfunction in CM patients and was correlated with death. Analysis of the cytokine response showed a strong induction of pro- and anti-inflammatory biomarkers in malaria patients. However, the magnitude of this response was significantly higher in CM than in NCM patients for inflammatory biomarkers while it was comparable in the two groups for the anti-inflammatory cytokines. Additionally, comparison of the biomarkers in the survivors versus the deceased of CM showed four pro-inflammatory analytes that were significantly higher in the deceased patients. Altogether, our results suggest a scenario in which a strong inflammatory response that was not properly contained led to organ failure and death during CM.

The involvement of the inflammatory response in the pathogenesis of severe malaria, including CM, is well documented (Clark *et al.*, 2008). The balance of pro- and anti-inflammatory cytokines, chemokines and growth factors is key to controlling parasite development without damages to host organs. Regarding the individual biomarkers, we found pro-inflammatory immune mediators increased in malaria patients with levels of IL-6 and IL-8 higher in CM compared to NCM individuals, and of eotaxin, IL-15, MCP-1 and TNF α elevated in deceased compared to survivors of CM. The association

of these cytokines and chemokines with malaria severity and/or poor outcome have been described before ([Clark et al., 2008](#)). TNF α is one of the first recognized pro-inflammatory biomarkers that play important role during malaria. With other Th1 type cytokines IL-1, IL-12 and IFN γ it contributes to the control of the infection ([Schofield & Grau, 2005](#)). However, elevated levels of TNF α were associated with disease severity in both children and adults ([Prakash et al., 2006](#); [Thuma et al., 2011](#)) and can discriminate between SM and UM ([Mahanta et al., 2015](#)). Similarly, IL-8 ([Berg et al., 2014](#); [Lyke et al., 2004](#)), IL-6 ([Jakobsen et al., 1994](#); [Lyke et al., 2004](#)), IL-15 ([Hu, 2013](#); [Ong'echa et al., 2011](#)) and MCP-1 ([MacMullin et al., 2012](#); [Quelhas et al., 2012](#)) were reported as increased during malaria.

In contrast to TNF α , IL-6, IL-8, IL-15 and MCP-1, eotaxin was not often mentioned in previous malaria studies. Interestingly, the level of eotaxin was higher in the CT individuals than in the malaria patients but the difference lost statistical significance after multiple testing adjustment. A significantly lower level of eotaxin was reported by [Requena et al. \(2014\)](#) in pregnant women exposed to malaria when compared to controls residing in malaria-free areas. Additionally, eotaxin was found as a negative predictor of hemoglobin level in children with SMA ([Ong'echa et al., 2011](#)). These observations suggest that eotaxin is downregulated during malaria and that it could be involved in pathogenesis. Eotaxin is a Th2-type chemokine that mediates eosinophil development and recruitment in host tissues ([Pope et al., 2001](#); [Queto et al., 2010](#)). Eotaxin is an important biomarker of allergic diseases ([Pope et al., 2001](#)) and polymorphism of its encoding gene influence total serum IgE level ([Batra et al., 2007](#); [Wang et al., 2007](#)). The role played by IgE in response to malaria infection is controversial with some studies claiming a protective function ([Bereczky et al., 2004](#); [Farouk et al., 2005](#)) while other associating IgE with disease severity ([Perlmann et al., 1994](#); [Perlmann et al., 1997](#); [Seka-Seka et al., 2004](#)). However, a recent study in a mouse model of experimental CM showed that animals genetically deficient for IgE or for the high affinity receptor for IgE were less susceptible to CM ([Porcherie et al., 2011](#)) supporting a role of IgE in the development of CM. The same study showed that CM pathogenesis was mediated by neutrophils expressing the high affinity receptor for IgE that homed to the brain and locally induced high levels of pro-inflammatory cytokines ([Porcherie et al., 2011](#)). Whether this function could be translated to human is unknown. However, a recent study reported an elevated neutrophil count that correlated with expression levels of the pro-inflammatory mediators IL-1 β and IL-8 in human severe malaria ([Mahanta et al., 2015](#)). Altogether, these observations support the hypothesis that elevated levels of eotaxin result in higher production of IgE and deleterious effects during human malaria. If this is the case, the downregulation of eotaxin observed previously ([Requena et al., 2014](#)) and in this study might be a mechanism that protects against the damages caused by IgE during malaria. This hypothesis is consistent with higher levels of eotaxin observed in deceased compared to survivors of CM. However it needs to be tested in other studies.

Besides eotaxin, IL-5, another Th2 type cytokine displayed a remarkable profile in this study with its level significantly decreased in CM compared to NCM patients ([Fig. 3](#)). IL-5 is a regulatory cytokine that cooperates with eotaxin in the development and recruitment of eosinophils ([Nussbaum et al., 2013](#)). A previous study reported elevated levels of IL-5 in mild compared to severe malaria patients ([Prakash et al., 2006](#)) suggesting a protective

role of this cytokine. This hypothesis is consistent with a recent report of a mouse study demonstrating a protection of rodent against experimental CM by IL-33 treatment (*Besnard et al., 2015*). The protection against CM was mediated by IL-5 independently of eosinophils, implying a mechanism that does not involve eotaxin.

In conclusion, our study confirms previously reported inflammatory response during malaria. Our findings support the idea of a strong induction of pro-inflammatory immune mediators that was not matched by the production of regulatory, anti-inflammatory biomarkers as the cause of death during CM. Additionally, our results suggests the involvement of eotaxin and of IL-5 in CM development and outcome.

ACKNOWLEDGEMENTS

We would like to thank Theresa Wan-Chen Yap for her help in the dosage of the biomarkers. We are grateful to Dr Becaye Fall, Dr Pape Samba Fall and Dr Ronald Perraut for their constructive suggestions and for stimulating discussions.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was supported by University of Malaya-Ministry of Education (UM-MoE) High Impact Research (HIR) Grant UM.C/625/1/HIR/MoE/CHAN/13/6 (account no. H-50001-A000034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

University of Malaya-Ministry of Education (UM-MoE) High Impact Research (HIR) Grant: UM.C/625/1/HIR/MoE/CHAN/13/6.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Yakhya Dieye conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables.
- Babacar Mbengue conceived and designed the experiments, performed the experiments, analyzed the data, reviewed drafts of the paper.
- Shobha Dagamajalu performed the experiments.
- Mouhamadou Mansour Fall diagnosis of malaria, determination of blood parameters, treatment of patients.
- Mun Fai Loke contributed reagents/materials/analysis tools.
- Cheikh Momar Nguer analyzed the data, prepared figures and/or tables.
- Alassane Thiam performed the experiments, prepared figures and/or tables.
- Jamuna Vadivelu contributed reagents/materials/analysis tools, reviewed drafts of the paper.

- Alioune Dieye conceived and designed the experiments, contributed reagents/materials/analysis tools, reviewed drafts of the paper.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Université Cheikh Anta Diop de Dakar's institutional research ethics committee; Protocol Number 001/2015/CER/UCAD.

Data Availability

The following information was supplied regarding data availability:

The raw data has been supplied as a Supplemental Dataset.

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.1965#supplemental-information>.

REFERENCES

- Batra J, Rajpoot R, Ahluwalia J, Devarapu SK, Sharma SK, Dinda AK, Ghosh B. 2007.** A hexanucleotide repeat upstream of eotaxin gene promoter is associated with asthma, serum total IgE and plasma eotaxin levels. *Journal of Medical Genetics* **44**:397–403 DOI [10.1136/jmg.2006.046607](https://doi.org/10.1136/jmg.2006.046607).
- Bereczky S, Montgomery SM, Troye-Blomberg M, Rooth I, Shaw MA, Farnert A. 2004.** Elevated anti-malarial IgE in asymptomatic individuals is associated with reduced risk for subsequent clinical malaria. *International Journal for Parasitology* **34**:935–942 DOI [10.1016/j.ijpara.2004.04.007](https://doi.org/10.1016/j.ijpara.2004.04.007).
- Berg A, Patel S, Gonca M, David C, Otterdal K, Ueland T, Dalen I, Kvaloy JT, Mollnes TE, Aukrust P, Langeland N. 2014.** Cytokine network in adults with falciparum Malaria and HIV-1: increased IL-8 and IP-10 levels are associated with disease severity. *PLoS ONE* **9**:e114480 DOI [10.1371/journal.pone.0114480](https://doi.org/10.1371/journal.pone.0114480).
- Besnard AG, Guabiraba R, Niedbala W, Palomo J, Reverchon F, Shaw TN, Couper KN, Ryffel B, Liew FY. 2015.** IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. *PLoS Pathog* **11**:e1004607 DOI [10.1371/journal.ppat.1004607](https://doi.org/10.1371/journal.ppat.1004607).
- Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CL, Smith DL, Hay SI, Cibulskis RE, Gething PW. 2015.** The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature* **526**:207–211 DOI [10.1038/nature15535](https://doi.org/10.1038/nature15535).
- Clark IA, Alleva LM, Budd AC, Cowden WB. 2008.** Understanding the role of inflammatory cytokines in malaria and related diseases. *Travel Medicine and Infectious Disease* **6**:67–81 DOI [10.1016/j.tmaid.2007.07.002](https://doi.org/10.1016/j.tmaid.2007.07.002).

- Crompton PD, Moebius J, Portugal S, Waisberg M, Hart G, Garver LS, Miller LH, Barillas-Mury C, Pierce SK. 2014.** Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. *Annual Review of Immunology* 32:157–187 DOI [10.1146/annurev-immunol-032713-120220](https://doi.org/10.1146/annurev-immunol-032713-120220).
- Da Costa AG, Antonelli LR, Costa PA, Pimentel JP, Garcia NP, Tarrago AM, Dos Santos Mdo P, Nogueira PA, Hekcmann MI, Sadahiro A, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. 2014.** The robust and modulated biomarker network elicited by the *Plasmodium vivax* infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. *Journal of Immunology Research* 2014: 318250 DOI [10.1155/2014/318250](https://doi.org/10.1155/2014/318250).
- Deloron P, Roux Lombard P, Ringwald P, Wallon M, Niyongabo T, Aubry P, Dayer JM, Peyron F. 1994.** Plasma levels of TNF-alpha soluble receptors correlate with outcome in human falciparum malaria. *European Cytokine Network* 5:331–336.
- Doolan DL, Dobano C, Baird JK. 2009.** Acquired immunity to malaria. *Clinical Microbiology Reviews* 22:13–36, Table of Contents DOI [10.1128/CMR.00025-08](https://doi.org/10.1128/CMR.00025-08).
- Espie E, Diene Sarr F, Diop F, Faye J, Richard V, Tall A, Toure Balde A. 2015.** Spatio-temporal variations in malaria incidence in children less than 10 years old, health district of Sokone, Senegal, 2010–2013. *PLoS ONE* 10:e0137737 DOI [10.1371/journal.pone.0137737](https://doi.org/10.1371/journal.pone.0137737).
- Farouk SE, Dolo A, Berezky S, Kouriba B, Maiga B, Farnert A, Perlmann H, Hayano M, Montgomery SM, Doumbo OK, Troye-Blomberg M. 2005.** Different antibody- and cytokine-mediated responses to *Plasmodium falciparum* parasite in two sympatric ethnic tribes living in Mali. *Microbes and Infection* 7:110–117 DOI [10.1016/j.micinf.2004.09.012](https://doi.org/10.1016/j.micinf.2004.09.012).
- Frosch AE, John CC. 2012.** Immunomodulation in *Plasmodium falciparum* malaria: experiments in nature and their conflicting implications for potential therapeutic agents. *Expert Review of Anti-infective Therapy* 10:1343–1356 DOI [10.1586/eri.12.118](https://doi.org/10.1586/eri.12.118).
- Hu WC. 2013.** Human immune responses to *Plasmodium falciparum* infection: molecular evidence for a suboptimal TH17 bias over ideal and effective traditional TH1 immune response. *Malaria Journal* 12:Article 392 DOI [10.1186/1475-2875-12-392](https://doi.org/10.1186/1475-2875-12-392).
- Jakobsen PH, Morris-Jones S, Theander TG, Hviid L, Hansen MB, Bendtzen K, Ridley RG, Greenwood BM. 1994.** Increased plasma levels of soluble IL-2R are associated with severe *Plasmodium falciparum* malaria. *Clinical and Experimental Immunology* 96:98–103.
- Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey JO, Nkrumah FK, Behr C, Hviid L. 1998.** Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. *Lancet* 351:1768–1772 DOI [10.1016/S0140-6736\(97\)09439-7](https://doi.org/10.1016/S0140-6736(97)09439-7).
- Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, Kone A, Harley R, Plowe CV, Doumbo OK, Sztein MB. 2004.** Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and

- IL-12(p70) in Malian children with severe *Plasmodium falciparum* malaria and matched uncomplicated malaria or healthy controls. *Infection and Immunity* 72:5630–5637 DOI [10.1128/IAI.72.10.5630-5637.2004](https://doi.org/10.1128/IAI.72.10.5630-5637.2004).
- MacMullin G, Mackenzie R, Lau R, Khang J, Zhang H, Rajwans N, Liles WC, Pillai DR. 2012.** Host immune response in returning travellers infected with malaria. *Malaria Journal* 11:Article 148 DOI [10.1186/1475-2875-11-148](https://doi.org/10.1186/1475-2875-11-148).
- Mahanta A, Kar SK, Kakati S, Baruah S. 2015.** Heightened inflammation in severe malaria is associated with decreased IL-10 expression levels and neutrophils. *Innate Immunity* 21:546–552 DOI [10.1177/1753425914561277](https://doi.org/10.1177/1753425914561277).
- Nussbaum JC, Van Dyken SJ, Von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, Thornton EE, Krummel MF, Chawla A, Liang HE, Locksley RM. 2013.** Type 2 innate lymphoid cells control eosinophil homeostasis. *Nature* 502:245–248 DOI [10.1038/nature12526](https://doi.org/10.1038/nature12526).
- Olliaro P. 2008.** Editorial commentary: mortality associated with severe *Plasmodium falciparum* malaria increases with age. *Clinical Infectious Diseases* 47:158–160 DOI [10.1086/589288](https://doi.org/10.1086/589288).
- Ong'echa JM, Davenport GC, Vulule JM, Hittner JB, Perkins DJ. 2011.** Identification of inflammatory biomarkers for pediatric malarial anemia severity using novel statistical methods. *Infection and Immunity* 79:4674–4680 DOI [10.1128/IAI.05161-11](https://doi.org/10.1128/IAI.05161-11).
- Perlmann H, Helmby H, Hagstedt M, Carlson J, Larsson PH, Troye-Blomberg M, Perlmann P. 1994.** IgE elevation and IgE anti-malarial antibodies in *Plasmodium falciparum* malaria: association of high IgE levels with cerebral malaria. *Clinical and Experimental Immunology* 97:284–292.
- Perlmann P, Perlmann H, Flyg BW, Hagstedt M, Elghazali G, Worku S, Fernandez V, Rutta AS, Troye-Blomberg M. 1997.** Immunoglobulin E, a pathogenic factor in *Plasmodium falciparum* malaria. *Infection and Immunity* 65:116–121.
- Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J. 1994.** High levels of circulating IL-10 in human malaria. *Clinical and Experimental Immunology* 95:300–303.
- Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaehi KI, Foster PS, Rothenberg ME. 2001.** IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. *Journal of Allergy and Clinical Immunology* 108:594–601 DOI [10.1067/mai.2001.118600](https://doi.org/10.1067/mai.2001.118600).
- Porcherie A, Mathieu C, Peronet R, Schneider E, Claver J, Commere PH, Kiefer-Biasizzo H, Karasuyama H, Milon G, Dy M, Kinet JP, Louis J, Blank U, Mecheri S. 2011.** Critical role of the neutrophil-associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria. *Journal of Experimental Medicine* 208:2225–2236 DOI [10.1084/jem.20110845](https://doi.org/10.1084/jem.20110845).
- Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S. 2006.** Clusters of cytokines determine malaria severity in *Plasmodium falciparum*-infected patients from endemic areas of Central India. *Journal of Infectious Diseases* 194:198–207 DOI [10.1086/504720](https://doi.org/10.1086/504720).

- Quelhas D, Puyol L, Quinto L, Nhampossa T, Serra-Casas E, Macete E, Aide P, Sanz S, Aponte JJ, Doolan DL, Alonso PL, Menendez C, Dobano C. 2012. Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to *Plasmodium falciparum* in Mozambican children. *BMC Immunology* 13:5 DOI 10.1186/1471-2172-13-5.
- Queto T, Gaspar-Elsas MI, Masid-de-Brito D, Vasconcelos ZF, Ferraris FK, Penido C, Cunha FQ, Kanaoka Y, Lam BK, Xavier-Elsas P. 2010. Cysteinyl-leukotriene type 1 receptors transduce a critical signal for the up-regulation of eosinophilopoiesis by interleukin-13 and eotaxin in murine bone marrow. *Journal of Leukocyte Biology* 87:885–893 DOI 10.1189/jlb.1108709.
- Requena P, Campo JJ, Umbers AJ, Ome M, Wangnapi R, Barrios D, Robinson LJ, Samol P, Rosanas-Urgell A, Ubillos I, Mayor A, Lopez M, De Lazzari E, Arevalo-Herrera M, Fernandez-Becerra C, Del Portillo H, Chitnis CE, Siba PM, Bardaji A, Mueller I, Rogerson S, Menendez C, Dobano C. 2014. Pregnancy and malaria exposure are associated with changes in the B cell pool and in plasma eotaxin levels. *Journal of Immunology* 193:2971–2983 DOI 10.4049/jimmunol.1401037.
- Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A, Diatta B, Seignot P, Roussillon C. 1997. Prognostic value of anti-*Plasmodium falciparum*-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. *Infection and Immunity* 65:3271–3276.
- Schofield L, Grau GE. 2005. Immunological processes in malaria pathogenesis. *Nature Reviews Immunology* 5:722–735 DOI 10.1038/nri1686.
- Seka-Seka J, Brouh Y, Yapo-Crezoit AC, Atseye NH. 2004. The role of serum immunoglobulin E in the pathogenesis of *Plasmodium falciparum* malaria in Ivorian children. *Scandinavian Journal of Immunology* 59:228–230 DOI 10.1111/j.0300-9475.2004.01337.x.
- Storm J, Craig AG. 2014. Pathogenesis of cerebral malaria— inflammation and cytoadherence. *Frontiers in Cellular and Infection Microbiology* 4:Article 100 DOI 10.3389/fcimb.2014.00100.
- Thuma PE, Van Dijk J, Bucala R, Debebe Z, Nekhai S, Kuddo T, Nouraie M, Weiss G, Gordeuk VR. 2011. Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia. *Journal of Infectious Diseases* 203:211–219 DOI 10.1093/infdis/jiq041.
- Torrentino-Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, Dionne P, Ba Fall K, Nakoulima A, Diatta B, Dieme Y, Menard D, Wade B, Pradines B. 2014. Limited polymorphisms in k13 gene in *Plasmodium falciparum* isolates from Dakar, Senegal in 2012–2013. *Malaria Journal* 13:Article 472 DOI 10.1186/1475-2875-13-472.
- Trape JF, Tall A, Sokhna C, Ly AB, Diagne N, Ndiath O, Mazonot C, Richard V, Badiane A, Dieye-Ba F, Faye J, Ndiaye G, Diene Sarr F, Roucher C, Bouganali C, Bassene H, Toure-Balde A, Roussillon C, Perraut R, Spiegel A, Sarthou JL, Da Silva LP, Mercereau-Puijalon O, Druilhe P, Rogier C. 2014. The rise and

fall of malaria in a West African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study. *The Lancet Infectious Diseases* **14**:476–488 DOI [10.1016/S1473-3099\(14\)70712-1](https://doi.org/10.1016/S1473-3099(14)70712-1).

Walther M, Tongren JE, Andrews L, Korbel D, King E, Fletcher H, Andersen RF, Bejon P, Thompson F, Dunachie SJ, Edele F, De Souza JB, Sinden RE, Gilbert SC, Riley EM, Hill AV. 2005. Upregulation of TGF-beta, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. *Immunity* **23**:287–296 DOI [10.1016/j.immuni.2005.08.006](https://doi.org/10.1016/j.immuni.2005.08.006).

Wang TN, Chiang W, Tseng HI, Chu YT, Chen WY, Shih NH, Ko YC. 2007. The polymorphisms of Eotaxin 1 and CCR3 genes influence on serum IgE, Eotaxin levels and mild asthmatic children in Taiwan. *Allergy* **62**:1125–1130 DOI [10.1111/j.1398-9995.2007.01485.x](https://doi.org/10.1111/j.1398-9995.2007.01485.x).

White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. *Lancet* **383**:723–735 DOI [10.1016/S0140-6736\(13\)60024-0](https://doi.org/10.1016/S0140-6736(13)60024-0).

WHO. 2000. Severe falciparum malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **94(Suppl1)**:1–90.

WHO. 2015. *World Malaria report 2015*. Geneva: World Health Organization.